Cellentia, Inc.

Cellentia is a specialized contract research organization (CRO) providing comprehensive bioassay and analytical services to support research and drug development. The company specializes in custom bioassay development, patient-derived organoid services, and assay platforms including Meso-Scale Discovery (MSD), AAV-based assays, and ELISA. Additional capabilities include PBMC isolation and blood processing, mycoplasma detection, and organoid culturing services.

The company offers a portfolio of patient-derived 3D tumor organoid lines for purchase, established from primary tumor tissue and circulating tumor cells. These models are designed to capture tumor complexity, heterogeneity, and clinically relevant treatment responses, supporting drug screening, translational oncology research, biomarker discovery, and precision medicine development.